Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

Depomed Inc (NASDAQ: DEPO)

$10.39 USD -$0.24 (-2.26%)
Last Price $10.39
Net Change $-0.24 (-2.26%)
Bid $0
Ask Price $0
Open Price $10.61
Previous Close Price $10.63
High Price $10.77
Low Price $10.18
Number of Trades 6,706
Volume 1,356,455
Fifty Two Week High $27.02 (2016-09-30)
Fifty Two Week Low $9.5 (2017-05-10)
Average Daily Volume 1,649,538
Share Outstanding 62,340 Shares
Total Dividend Payout 0/yr
Dividend Yield 0%
1st Quarter Earnings $0.07 (2017-05-09)
2nd Quarter Earnings $0.48 (2017-02-21)
3nd Quarter Earnings $0.28 (2016-11-07)
4th Quarter Earnings $0.27 (2016-08-03)
PE Ratio $0
EPS Growth $19.31
Recent Earnings $0.07
Annual EPS $-1.53
Last Quarter EPS $
Market Capitalization $0.65B
Insider Shareholders % 0.0512%
Annual Revenue $0B
No. Shares Outstanding 62,340
Inst. Shareholder % 93.04%
Annual Net Income $-0.09B
TTM Net Profit Margin $-21.41
1-Year Return -46.77%
3-Year Return -8.28%
5-Year Return 94.33%
5-Year Revenue Growth 242.86%
5-Year Earnings Growth -368.52%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 0%
Change in EPS YTD 19.309999%
Dividends per Share $
Stock Split Ratio
Beta 1.32
Depomed, Inc. is a specialty pharmaceutical company utilizing its innovative AcuForm drug delivery technology to develop novel oral products and improved, extended release formulations of existing oral drugs. AcuForm-based products are designed to provide once- daily administration and reduced side effects, improving patient convenience, compliance and pharmacokinetic profiles. ProQuin XR extended-release tablets have been approved by the FDA for the once-daily treatment of uncomplicated urinary tract infections and are currently being marketed in the United States. In addition, once-daily Glumetza has been approved for use in adults with type two diabetes and is currently being marketed in the United States and Canada. The company is currently evaluating Gabapentin GR for the treatment of two pain indications, postherpetic neuralgia and diabetic peripheral neuropathy, and menopausal hot flashes.

DEPO News & Stock Updates